Why liver disease newco Alentis is aiming for one of largest Swiss A rounds
BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up
Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.
Founded in
